Bright Minds Biosciences ... (DRUG)
35.34
-1.90 (-5.10%)
At close: Mar 03, 2025, 3:59 PM
34.92
-1.18%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 32 |
| Market Cap | 248.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.14 |
| PE Ratio (ttm) | -252.41 |
| Forward PE | -20.2 |
| Analyst | Buy |
| Ask | 39.89 |
| Volume | 72,358 |
| Avg. Volume (20D) | 83,956 |
| Open | 36.62 |
| Previous Close | 37.24 |
| Day's Range | 34.88 - 36.62 |
| 52-Week Range | 0.93 - 79.02 |
| Beta | 0.49 |
About DRUG
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Bra...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 22, 2021
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol DRUG
Website https://brightmindsbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for DRUG stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 140.54% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
-1.24%
Bright Minds Biosciences shares are trading higher...
Unlock content with
Pro Subscription
4 months ago
+1.72%
Bright Minds Biosciences shares are trading higher after the company announced a collaboration with Firefly Neuroscience to provide a full analysis of the EEG data in the BREAKTHROUGH study.
